Leadership Center Administration

总结 在过去的15年里，食物过敏研究急剧增加，为我们提供了潜在的治疗方法。 和预防战略。本申请中提出的研究议程的总体目标是定位 CoFAR是食物过敏研究的国际领导者，包括疾病的最佳表征 和下一代治疗方法的发展。研究议程将首先基于 最好的科学，但为了最大限度地提高生产力，我们还需要明智地计划，使所有可用的 资源可以得到最大限度的利用。因此，研究议程需要仔细选择， 阶段协议不仅基于其推进该领域的潜力，而且还仔细考虑了 其他可能正在开发的新疗法，以及一项研究如何为下一项研究提供信息。最后 总体研究战略还需要平衡SACC和联合体中每个CRU的工作量。 这一总体议程将通过以下主要组成部分来实现：1）实施领导 团队能够提供最佳的管理财团，包括财务，运营， 管理方面，以及方案制定和实施、数据收集和分析，以及 出版物和演示文稿，以及明智的财务管理。罗伯特·伍德博士将领导这个团队， 共同PI博士韦斯利伯克斯和玛莎威尔斯卡普，谁将领导生物标志物设施和机会基金， 分别该团队还将包括一名财务管理员以及一名经验丰富的赠款 约翰霍普金斯大学的管理团队。领导团队将与国家工业发展研究所和SACC密切合作， 共同提供联盟内所有临床操作的日常管理。2)发展 必要的委员会结构，以指导和实施联盟的行政和临床运作。 3)建立一个财务管理结构，以最佳方式利用所有联邦反洗钱委员会的资金和资源。 4)将生物标志物设施整合到每个临床方案中。4)最大限度地利用资源， 机会基金扩大食物过敏及其治疗机制研究的潜力。 预计至少有3项方案，包括临床试验和非干预性研究， 在7年的供资期内启动和完成，这可能会增加到5个甚至6个议定书， 每个研究的规模、持续时间和复杂性。如果成功，这项研究议程将不仅定义 未来7年的CoFAR，但也将为未来十年的食物过敏研究建立平台。

Summary Food allergy research has increased dramatically over the past 15 years providing us with potential therapeutic and prevention strategies. The overarching goal of the research agenda proposed in this application is to position CoFAR as the international leader in the study of food allergy, including optimal characterization of the disease and development of the next generation of treatments. The research agenda will be based first and foremost on the best possible science, but to maximize productivity we will also need to plan judiciously so that all available resources can be used to their utmost capacity. Therefore, the research agenda will need to carefully select and stage protocols based not just on their potential to advance the field, but also with careful consideration regarding other novel treatments that may be under development, and how one study may inform the next. Finally, the overall research strategy will also need to balance the work load of the SACCC and each CRU in the consortium. This overall agenda will be accomplished through the following major components: 1) To implement a leadership team capable of providing optimal administration of the Consortium, including financial, operational, and managerial aspects, as well as protocol development and implementation, data collection and analysis, and publications and presentations, with judicious financial management. Dr. Robert Wood will lead this team, with co-PIs Drs. Wesley Burks and Marsha Wills-Karp, who will lead the Biomarker Facility and Opportunity Fund, respectively. The team will also include a financial administrator as well as a highly experienced grants management group at Johns Hopkins. The leadership team will work closely with the NIAID and SACCC, together providing day-to-day management of all clinical operations within the consortium. 2) To develop the necessary committee structure to guide and implement the Consortium’s administrative and clinical operations. 3) To develop a structure of financial management that will make optimal use of all CoFAR funds and resources. 4) To integrate the Biomarker Facility into each clinical protocol. 4) To maximally leverage the resources and potential of the Opportunity Fund to expand the mechanistic study of food allergy and its treatment. It is anticipated that a minimum of 3 protocols, including both clinical trials and non-interventional studies, will be initiated and completed over the seven-year funding period, and this could rise to 5 or even 6 protocols depending on the size, duration, and complexity of each study. If successful, this research agenda will define not just the next 7 years of CoFAR, but will also establish the platform for the next decade(s) of food allergy research.